Clinical trials: Pregnancy, Multiple
Carcinoma, Renal Cell
CPG 7909 in Patients Wih Stage IV Renal Cell Cancer
CPG 7909 given alone to patients with renal cell cancer after their nephrectomy. CPG 7909 is as a subcutaneous injection once per week for up to 24 weeks. Up to 40 patients will be included in the study.
- Trial name
- NCT00043407
- Testing
- CPG 7909
- Volunteers
- 42 people
- Sponsor
- Pfizer
Bacterial Vaginosis
Treatment of Bacterial Vaginosis With Oral Tinidazole
The purpose of this study is to confirm the safety and efficacy of oral tinidazole for the treatment of bacterial vaginosis.
- Trial name
- NCT00229216
- Testing
- Tinidazole
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Mission Pharmacal
Pregnancy, Pregnant Women
A Non-interventional Multi-country Cohort Study to Assess the Safety of EVUSHELD™ During Pregnancy
Multi-country, non-interventional cohort study.The objective of the study is to characterise the risk of pregnancy and offspring (neonatal and infant) outcomes in pregnancies with and without exposure to EVUSHELD (used as a…
- Conditions
- Pregnancy, Pregnant Women, Pregnancy Outcome
- Trial name
- O-STEREO (NCT05847140)
- Sponsor
- AstraZeneca
Hepatorenal Syndrome, Acute Kidney Injury
Study to Evaluate R2R01 Plus Terlipressin Versus Terlipressin Alone in Patients With Hepatorenal Syndrome
This study aims to evaluate the safety, tolerability and efficacy of R2R01 combined with terlipressin as compared to terlipressin alone in the treatment of patients with HRS-AKI
- Trial name
- NCT05875948
- Testing
- R2R01, Terlipressin
- Where
- 7 sites in United States
- Volunteers
- 95 people
- Sponsor
- River 2 Renal Corp.
Gynecological Malignant Tumor, Solid Tumor
A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Recurrent or Metastatic Gynecological Malignancies
A phase Ib/II clinical study to evaluate the safety, tolerability, pharmacokinetics and efficacy of BL-B01D1 for injection in patients with multiple solid tumors, including recurrent or metastatic gynecological malignancies.
- Trial name
- NCT05803018
- Testing
- BL-B01D1
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Hypertension, Renal
RENABLATE-II Feasibility Study of Catheter Based Renal Denervation to Treat Resistant Hypertension - 157
This is a prospective, multi-center, non-randomized, feasibility study to assess the safety and effectiveness of renal artery sympathetic denervation using the investigational devices in subjects with resistant hypertension.
- Trial name
- RENABLATE-II (NCT02095691)
- Testing
- Celsius® ThermoCool® Renal Denervation
- Volunteers
- 19 people
- Sponsor
- Biosense Webster, Inc.
NSCLC, SCLC
A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors
This is a Phase 1/2a, first-in-human, open-label study of JAB-8263, this study has two parts: solid tumor dose escalation and expansion study and hematology tumor dose escalation and expansion study.
- Conditions
- NSCLC, SCLC, CRPC, ESCC
- Trial name
- NCT04686682
- Testing
- JAB-8263
- Where
- China
- Volunteers
- 152 people
- Sponsor
- Jacobio Pharmaceuticals Co., Ltd.
End Stage Renal Disease
A Safety Study of Pentoxifylline for the Treatment of Anemia
Chronic kidney disease (CKD) patients have increased levels of inflammation and oxidative stress, which in turn contribute to anemia and cardiovascular disease.
- Trial name
- NCT01102218
- Testing
- Erythropoietin, Pentoxifylline
- Where
- 10 sites in United States
- Volunteers
- 48 people
- Sponsor
- Fresenius Medical Care North America
Female Infertility
Recombinant Follicle-stimulating Hormone in Treatment for Infertility
This is a randomized multi-centre, assessor-blind, parallel-group study to be conducted in 250 women in the age group of 20 to 39 years (both inclusive), who are indicated to undergo COS as part of assisted reproductive…
- Trial name
- REFRESH (NCT05266924)
- Testing
- Recombinant Human Follicle Stimulating Hormone 900 IU (66.0 μg) / 1.5mL Solution for Injection in Prefilled Pen
- Where
- India
- Volunteers
- 250 people
- Sponsor
- Bharat Serums and Vaccines Limited
Bacterial Vaginosis
DARE-BV1 in the Treatment of Bacterial Vaginosis (DARE-BVFREE)
This is a multicenter, randomized, double-blind, placebo-controlled study of DARE-BV1 (clindamycin phosphate vaginal gel, 2%) (QD x 1 day) compared to placebo vaginal gel (HEC Universal Placebo Gel) (QD × 1 day) for the treatment…
- Trial name
- NCT04370548
- Testing
- DARE-BV1clindamycin phosphate vaginal gel, 2%
- Where
- 10 sites in United States
- Volunteers
- 307 people
- Sponsor
- Daré Bioscience, Inc.
Healthy Pregnant Women
Milk Free From A1-Type β-Casein on Inflammation, Gastrointestinal Tolerance, and Pregnancy Outcomes
The aim of the study is to compare the effects of conventional Ultra High Temperature (UHT) milk containing both A1 and A2 type β-caseins (CON) with a2 UHT Milk containing A2 type β-casein only (A1PF) on inflammation, tolerance…
- Trial name
- NCT06980376
- Testing
- a2 UHT milk, Conventional UHT Milk
- Where
- 6 sites in China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- a2 Milk Company Ltd.
Overactive Bladder (OAB), Failed Any OAB Pharmacotherapy
Open Label Study to Evaluate the Efficacy of the Home Based Electrical Transcutaneous URIS I in the Treatment of Overactive Bladder (OAB).
Open label Study to Evaluate the Efficacy of the Home Based Electrical Transcutaneous NeuroModulation (eTNM) Treatment Via Nerve Stimulator URIS I in the Treatment of Overactive Bladder.
- Trial name
- NCT05211193
- Testing
- eTNM delivered by URIS I nerve stimulation device
- Where
- Czechia
- Volunteers
- 40 people
- Sponsor
- Stimvia s.r.o.
Urinary Tract Infections (UTIs)
Evaluation of the Effectiveness and Safety of a Vaginal Gel for Prevention of Recurrent Urinary Tract Infections
Urinary Tract Infections (UTIs) are among the most common bacterial infections. Although they are typically treated effectively with antibiotics, recurrence is a frequent and troublesome issue.
- Trial name
- UTI (NCT07233473)
- Testing
- Multi-Gyn UT Protect gel
- Where
- France
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Karo Pharma AB
CAH - Congenital Adrenal Hyperplasia
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-74788 (Crinecerfont) in Pediatric Participants With Congenital Adrenal Hyperplasia
This is a Phase 2, open-label, multiple-dose, study to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of NBI-74788 (crinecerfont) in pediatric participants (14 to 17 years of age) with a…
- Trial name
- NCT04045145
- Testing
- Crinecerfont
- Where
- 6 sites in United States
- Volunteers
- 8 people
- Sponsor
- Neurocrine Biosciences
Kidney Failure, Acute
Study to Evaluate the Safety and Efficacy of the Renal Assist Device in Patients With Acute Renal Failure
The purpose of this study is to evaluate the safety and efficacy of the RAD to determine whether the RAD is effective in reducing mortality in patients with Acute Renal Failure due to Acute Tubule Necrosis and to evaluate the…
- Trial name
- NCT00280072
- Testing
- Renal Assist Device
- Where
- 16 sites in United States
- Sponsor
- RenaMed Biologics
Congenital Adrenal Hyperplasia, CAH - Congenital Adrenal Hyperplasia
Study of SPR001 in Adults With Classic Congenital Adrenal Hyperplasia
This is a multicenter Phase 2, multiple dose, dose escalation study to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of SPR001 in adult patients with classic congenital adrenal hyperplasia (CAH).
- Trial name
- NCT03257462
- Testing
- SPR001
- Where
- 9 sites in United States
- Volunteers
- 24 people
- Sponsor
- Spruce Biosciences
Renal Impairment
A Study to Investigate the Effect of Renal Function and Hemodialysis on the Pharmacokinetics (PK) of RO7079901
This is a multi-center, non-randomized, open-label, two-part study to investigate the effect of renal function and hemodialysis on PK of RO7079901.
- Trial name
- NCT02975388
- Testing
- RO7079901
- Where
- 5 sites in United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Carcinoma, Renal Cell
Study Of Safety And Tolerability Of GW786034 Given With Lapatinib In Cancer Patients
This Phase I, dose finding study evaluates the safety and tolerability of lapatinib, a dual tyrosine kinase inhibitor, and GW786034, an anti-angiogenesis agent, when given together.
- Trial name
- NCT00158782
- Testing
- GW786034, lapatinib
- Where
- 2 sites in United States, Netherlands
- Volunteers
- 75 people
- Sponsor
- GlaxoSmithKline
Chronic Kidney Disease, Hyperparathyroidism, Secondary
Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency
This study will evaluate the efficacy of CTAP101 Capsules versus placebo in reducing intact parathyroid hormone (iPTH) by at least 30% from pretreatment baseline; safety and tolerability of CTAP101 will also be evaluated
- Conditions
- Chronic Kidney Disease, Hyperparathyroidism, Secondary, Vitamin D Deficiency
- Trial name
- NCT01704079
- Testing
- CTAP101 30 μg capsules, Sugar pill to CTAP101 30 μg capsules
- Where
- United States
- Volunteers
- 216 people
- Sponsor
- OPKO IP Holdings II, Inc.
Urinary Incontinence
A Study to Measure the Effect of Tolterodine Extended Release on the Thickness of the Bladder Wall in Patients With Overactive Bladder
The main aim of the study is to investigate whether taking Tolterodine for overactive bladder symptoms can reduce the thickness of the bladder wall, as measured by intra-vaginal ultrasound.
- Trial name
- NCT00137397
- Testing
- Tolterodine ER
- Where
- 11 sites in United Kingdom
- Volunteers
- 80 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.